Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Intangibles (2023 - 2025)

Historic Intangibles for Cartesian Therapeutics (RNAC) over the last 3 years, with Q3 2025 value amounting to $150.6 million.

  • Cartesian Therapeutics' Intangibles changed 0.0% to $150.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $150.6 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Cartesian Therapeutics reported Intangibles of $150.6 million as of Q3 2025, which was down 0.0% from $150.6 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Intangibles peaked at $150.6 million during Q4 2023, and registered a low of $150.6 million during Q4 2023.
  • Over the past 3 years, Cartesian Therapeutics' median Intangibles value was $150.6 million (recorded in 2023), while the average stood at $150.6 million.
  • Data for Cartesian Therapeutics' Intangibles shows a peak YoY increase of 0.0% (in 2024) and a maximum YoY decrease of 0.0% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Cartesian Therapeutics' Intangibles stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then changed by 0.0% to $150.6 million in 2025.
  • Its last three reported values are $150.6 million in Q3 2025, $150.6 million for Q2 2025, and $150.6 million during Q1 2025.